None listed
Conditions
Interventions
Placebo Group:placebo
Low-Dose Intervention Group:Take low-dose interventional test food substances
High-Dose Intervention Group:Take high-dose interventional test food substances
Positive Comparator Group:Positive competing product
Sponsors
West China School of Public Health/West China Fourth Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Healthy adults aged 18 to 50 who can provide informed consent and are willing to cooperate with the study; 2. Will not take or receive probiotics/prebiotics/postbiotics (excluding yogurt), dietary fiber supplements, or other health products/medications/treatment measures (such as fecal transplantation, cosmetic medical procedures, etc.) that improve skin or regulate intestinal function from non-study sources during the study period; 3. Will not change existing dietary habits and exercise levels during the study period, and maintain normal diet and activities; 4. For subjects participating in skin testing via tape stripping: no use of bath scrubs on the forearms within 1 week prior to sampling, and no use of any products on the forearms within 12 hours prior to sampling.
Exclusion criteria
Exclusion criteria: 1.Diagnosed with chronic gastrointestinal diseases, including: history of active, uncontrolled inflammatory bowel disease (IBD) (ulcerative colitis, Crohn's disease, or indeterminate colitis); moderate to severe irritable bowel syndrome (IBS); infectious gastroenteritis, colitis, or gastritis; recurrent Clostridioides difficile infection or untreated Helicobacter pylori infection; malabsorption (e.g., celiac disease); 2.Having undergone major gastrointestinal surgery other than cholecystectomy and appendectomy within the past 5 years, or major intestinal resection at any time; 3.On the face or forearms: presence of skin lesions (including scars, blisters, papules, macules, etc.) or skin diseases (including ichthyosis, psoriasis, etc.) at baseline; or new onset of the above abnormalities during follow-up testing; 4.Having the following test results or medical history: significant liver enzyme abnormalities; history of kidney disease, endocrine diseases (e.g., diabetes mellitus, hyperthyroidism, gout), cardio-cerebrovascular diseases, hematopoietic system diseases, inflammatory diseases, or malignant tumors; infection with human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), or other known immunocompromising diseases; history of mental illness; 5.Body Mass Index (BMI) = 28 kg/m^2; 6.Being in pregnancy or lactation; 7.Current smokers; former smokers who have quit for less than 6 months; heavy drinkers (screened via the abbreviated AUDIT-C questionnaire—excluding females with a score >= 3 and males with a score >= 4); 8.Subjects with allergic diathesis or allergies to the intervention product; 9.Those who have received permanent dermal fillers; 10.Within the past 3 months: subjects who have undergone any cosmetic skin correction treatments or dermatological medical procedures on the face or forearms (specifically including: (1). Photoelectric treatments: laser, radiofrequency, intense pulsed light, picosecond therapy; (2). Minimally invasive treatments: microneedling, microdermabrasion, chemical peeling; (3). Injectable treatments: mesotherapy, hyaluronic acid filling, botulinum toxin injection, collagen introduction; (4). Medication therapy; (5). Others: laser hair removal, radiofrequency skin tightening, etc.); used medical-grade functional products (including all "medical device-class products") on the face/forearms (e.g., medical aesthetic clinic products containing high-concentration acids or retinol, growth factor products); received medical aesthetic-related home care (e.g., home radiofrequency devices, LED masks); 11.Within the past 1 month: used antibiotics, hormonal drugs (e.g., dexamethasone, hormonal contraceptives, etc.), or immunosuppressants (e.g., cyclosporine, azathioprine, methotrexate, etc.); continuously or regularly taken any probiotics/prebiotics/postbiotics, dietary fiber supplements, or other health products that improve skin condition or regulate intestinal flora (excluding yogurt); 12.Within the past 2 weeks: experienced diarrhea; used laxatives or antidiarrheal drugs; 13.Within the past 1 week: used anticholinergic drugs, anesthetics, antacids, non-steroidal anti-inflammatory drugs (NSAIDs), antihistamines, or bath scrubs; 14.Known history of substance use disorder; or use of illegal drugs or alcohol within 24 hours prior to baseline or follow-up sampling; 15.Discontinued the study product during the study period; or added/started using other drugs, health products, skin care p
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gut Microbiota Diversity;Epigenetic information; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytokines;Skin Collagen Content; | — |
Countries
China
Contacts
Public ContactXiaomeng Li
West China School of Public Health/West China Fourth Hospital
Outcome results
None listed